Hemab Therapeutics Holdings, Inc. — Q3 2026 Form 10-Q
Reporting period: Three and nine months ended September 30, 2026; filed November 10, 2026. Hemab is a clinical-stage biotechnology company developing therapies for bleeding and coagulation disorders. It has no approved products and has generated no product-sales revenue.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement amounts are unaudited and in millions unless noted.
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $24.6 | $14.6 | $64.4 | $41.5 |
| General and administrative expense | $5.1 | $2.5 | $15.0 | $8.1 |
| Total operating expenses | $29.8 | $17.1 | $79.4 | $49.7 |
| Net loss | $27.3 | $17.1 | $74.1 | $44.6 |
| Interest income | $3.4 | $0.2 | $7.5 | $1.0 |
| Net loss per share, basic and diluted | $0.58 | $18.04 | $2.84 | $47.12 |
Margins are not meaningful because the company has no revenue. Net losses increased year over year as R&D and G&A spending grew; higher interest income following the IPO partly offset operating costs. Per-share comparisons are affected by the IPO, preferred-stock conversion and stock split.
- Cash and cash equivalents: $239.1 million at September 30, 2026, versus $88.0 million at December 31, 2025.
- Marketable securities: $191.1 million, versus $97.5 million; cash, cash equivalents and marketable securities totaled $430.2 million.
- Cash flows, nine months: $72.5 million used in operations (prior year $44.8 million); $93.2 million used in investing; and $317.2 million provided by financing, principally net IPO proceeds.
- Balance sheet: Total assets were $442.7 million, total liabilities $13.4 million, and stockholders’ equity $429.3 million. Liabilities were principally accounts payable, accruals and lease obligations; the filing reports no material funded debt.
- Accumulated deficit: $256.0 million. Shares outstanding were 46,712,117 at September 30 and 46,730,608 at October 30, 2026.
Material changes and business developments
- Q3 operating expenses rose $12.7 million year over year. Management attributed the increase mainly to higher clinical and external R&D costs, headcount and equity compensation, discovery and consulting activity, and public-company professional fees.
- For the nine-month period, operating expenses increased $29.8 million and net loss increased $29.6 million year over year. R&D growth included SOLARA start-up and manufacturing work for sutacimig, HMB-003 clinical and development costs, and increased personnel and discovery spending.
- The May 2026 IPO raised approximately $346.7 million gross and $317.2 million net. All preferred stock converted into common stock at the IPO. The company also completed a Delaware corporate reorganization and a 22-for-one forward stock split.
- In November 2026, after quarter-end, Hemab reported that it had initiated SOLARA, a Phase 3 sutacimig trial in Glanzmann thrombasthenia. The open-label, single-arm study plans to enroll approximately 75 participants and compares treated bleeding rates during a 48-week treatment period with each participant’s 24-week run-in period. The selected dose is 0.2 mg/kg subcutaneously once weekly.
- Also after quarter-end, the company reported initial single-dose Phase 2b Factor VII deficiency data from two participants: adverse events were low grade and assessed as unrelated; prothrombin time shortened by more than 50% in both. Additional data were expected at ASH in December 2026.
- HMB-002 is in Phase 1/2 development for Von Willebrand Disease; additional trial data were expected in February 2027. Hemab dosed the first participant in its HMB-003 Phase 1 healthy-volunteer trial in September and expected initial clinical data in mid-2027.
Outlook, risks and unusual items
- Management expects continued operating losses and negative cash flows as clinical development advances. The MD&A says existing funds are expected to support operating and capital needs into 2029, subject to assumptions and risks; the liquidity note separately says funds should cover at least one year from issuance of the statements. The differing runway descriptions merit clarification.
- Key execution risks include clinical-trial outcomes, enrollment and manufacturing, the need for additional capital, and the possibility that regulators require additional studies. The FDA recommended that Hemab consider a randomized design for SOLARA; Hemab proceeded with the single-arm design, which the FDA may not consider sufficient to support approval.
- Hemab disclosed three Grade 2 thromboembolic events in its earlier sutacimig Phase 1/2 Glanzmann thrombasthenia trial, including events at higher exposure and one at 0.3 mg/kg. The company selected a lower Phase 3 dose, but says thrombotic risk may remain.
- Management said marketable securities mature within 12 months. At September 30, three securities with a combined fair value of $157.5 million were in unrealized loss positions; losses were primarily attributed to currency movements, and no impairment allowance was recorded.
- Disclosure controls and procedures were ineffective because of material weaknesses in the financial close process and information-technology controls. New and enhanced controls were being implemented, with effectiveness testing expected to begin in Q4 2026; remediation was not yet complete.
- Other notable obligations include contingent development milestones and royalties or profit shares under Novo Nordisk, Genmab and Gubra agreements. An amended Cambridge office lease provides for approximately $3.7 million in base rent over 66 months and an approximately $1.4 million contribution toward build-out costs; the new lease had not commenced by September 30.
Important facts for investors to verify
- Clarify the cash-runway wording: “into 2029” in MD&A versus “at least one year” in the liquidity note, and the assumptions underlying the estimate.
- Track SOLARA enrollment, safety monitoring and FDA feedback, including whether the single-arm design and its results will be considered adequate for approval.
- Review full and updated safety data for sutacimig, particularly thromboembolic events and the rationale for the selected Phase 3 dose.
- Confirm timing and completeness of planned sutacimig, HMB-002 and HMB-003 clinical updates, and assess trial progress against stated expectations.
- Monitor operating cash use, rising R&D costs, equity dilution and any future financing needs, as well as progress in remediating the disclosed material weaknesses.